AlphAIalphai — Financial news for AI agents
finance.yahoo.comJUL 235 min read$AGIO

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks Investment Research says Agios Pharmaceuticals (AGIO) is expected to report Q2 results on July 30. Consensus calls for a quarterly loss of $1.86 per share, up 3.6% YoY, and revenue of $22.68 million, up 82.2%. Zacks reports an Earnings ESP of +12.67% and a Zacks Rank of #3, implying a likely EPS beat.

Original reporting
finance.yahoo.com
Published Jul 23, 2026, 2:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 23, 2026, 3:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AGIOBullishMed
01

Why it matters

AGIO’s near-term trading setup is tied to whether reported EPS and related commentary exceed the consensus loss of $1.86 per share and $22.68 million revenue expectation.

02

Market read

Traders get a pre-earnings probabilistic framing (positive ESP) and the specific consensus EPS and revenue numbers to benchmark the upcoming print.

03

What to watch

The piece does not include any new trial, regulatory, or guidance details; the stock reaction may hinge more on management commentary and forward outlook than on EPS alone.

Relevance 4/10Novelty 5/10Timing: Into the July 30 Q2 earnings release.

Background

Zacks outlines consensus expectations for Agios Pharmaceuticals’ quarter ended June 2026 and uses its Earnings ESP framework to estimate the probability of an EPS surprise.

Company-level read

Ticker impact

$AGIOBullishMedium confidence
Context

Ahead of its July 30 Q2 release, Agios is expected to report a $1.86 EPS loss and has an Earnings ESP of +12.67%.

Expected impact

Bias toward upside reaction if results align with the implied beat probability; downside risk if the beat fails to materialize.

Evidence & confidence

The only company-specific, decision-relevant inputs provided are consensus EPS/revenue expectations plus the Earnings ESP (+12.67%) and Zacks Rank (#3). No new operational or guidance datapoints are disclosed beyond these pre-earnings estimates.

Market effects

Sector

Limited read-across for biotech broadly; this is primarily a single-name pre-earnings setup.

Regional

No specific regional spillover described.

Global

No global macro or cross-border catalyst mentioned.

Counterpoint

What could challenge this read

A positive Earnings ESP does not guarantee a beat, and the article notes negative ESP is not predictive of a miss, implying model risk around directionality.

Key entities

  • company
    Agios Pharmaceuticals

    Subject of the article, with pre-earnings consensus and Zacks Earnings ESP inputs ahead of Q2 results.

  • model
    Zacks Earnings ESP

    Compares Most Accurate Estimate vs Zacks Consensus Estimate; article reports AGIO’s ESP as +12.67%.

  • rating
    Zacks Rank

    Article states AGIO has a Zacks Rank of #3 (Hold).

Read at source← All news

Related articles

JUL 30
$AGIOMedAI 8/10

AGIOS PHARMACEUTICALS, INC. (AGIO): Results of Operations and Financial Condition

AGIOS PHARMACEUTICALS, INC. (AGIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 agio-73026xfyxex991earning.htm EX-99.1 Document Agios Reports Second Quarter 2026 Financial Results and Provides Business Update • Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 milli

SEC EDGAR 8-K6 min
JUL 22
$SNDKMed

Stocks Gain as Chipmakers Rebound

Stocks rose as chipmakers and AI-infrastructure shares rebounded. The iShares Semiconductor ETF (SOXX) gained over 3%, while Sandisk (SNDK), Micron (MU), Western Digital (WDC), and others rose. Bitcoin hit a 1-month high, lifting Coinbase (COIN) and Circle (CRCL). Hasbro (HAS) reported Q2 net revenue $1.14B and raised guidance; 3M (MMM) beat EPS and lifted outlook.

yahoo.com7 min
JUL 21
$AGIOMedAI 8/10

Agios Reports Neutral Sickle Cell Data, Decides To Stop Development - Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) reported Phase 2 top-line results for tebapivat in sickle cell disease. The 12-week study (59 patients) showed hemoglobin and hemolysis improvements across doses, with 43.8% to 47.1% meeting a primary hemoglobin response versus 33.3% on placebo. Agios said it will stop development because results did not provide sufficient clinical differentiation. AGIO shares were down 7.11% to $37.21.

benzinga.com3 min
JUL 21
$AGIOMed

Agios Pharmaceuticals stock falls on trial update By Investing.com

Agios Pharmaceuticals (NASDAQ:AGIO) shares fell 14% after the company said it will stop developing tebapivat for sickle cell disease based on Phase 2 results. In 59 patients, hemoglobin response rates were 43.8% (2.5 mg), 47.1% (5.0 mg), 29.4% (7.5 mg) versus 33.3% placebo. Agios remains focused on mitapivat, under FDA Priority Review, with a Nov 1, 2026 PDUFA date.

investing.com3 min
JUL 10
$AGIOMedAI 8/10

FDA Priority Review Sends Agios Pharmaceuticals (NASDAQ: AGIO) Stock Price Surging 13.8% As Sickle Cell Drug Gains Momentum

Agios Pharmaceuticals said the FDA granted priority review for its oral pyruvate kinase activator mitapivat for sickle cell disease. The company’s shares rose 13.8% for the week through Friday morning. Mitapivat is already approved for PK deficiency and thalassemia, and an accelerated approval decision is due by Nov. 1, subject to confirmatory REIGNITE 3 results.

foreignpolicyjournal.com3 min